The role of common variants in susceptibility to acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS), a group of rare clonal hematologic disorders characterized by dysplastic hematopoiesis and high mortality, remains unclear. These diseases may have a shared molecular basis and identifying germline loci associated with the risk for their development could be important. We performed AML and MDS genome-wide association studies (GWAS) in European Americans from the DISCOVeRY-BMT study population (2309 cases and 2814 controls). Association analysis based on subsets (ASSET) was used to conduct a summary statistics SNPbased analysis of MDS and AML subtypes. For each AML and MDS case and control we used PrediXcan to estimate the component of gene expression determined by their genetic profile and correlate this imputed gene expression level with risk of developing disease in a transcriptome-wide association study (TWAS). We identified an increased risk for de novo AML and MDS (OR=1.38, 95% CI, 1.26-1.51, Pmeta=2.8x10-12) in patients carrying the T allele at rs12203592 in Interferon Regulatory Factor 4 (IRF4), a transcription factor which regulates myeloid and lymphoid hematopoietic differentiation.
INTRODUCTION
Genome-wide association studies (GWAS) have been successful at identifying risk loci in several hematologic malignancies , including acute myeloid leukemia (AML) (1) (2) (3) .
Recently genomic studies have identified common susceptibility loci between chronic lymphocytic leukemia (CLL), hodgkin lymphoma (HL), and multiple myeloma demonstrating shared genetic etiology between these B-cell malignancies (BCM) (4) (5) (6) .
Given the evidence of a shared genetic basis across BCM and the underlying genetic predisposition for AML and myelodysplastic syndromes (MDS) observed in family, epidemiological, and genetic association studies (1, (7) (8) (9) , we hypothesized that germline variants may contribute to both AML and MDS development. Using the DISCOVeRY-BMT study population (2309 cases and 2814 controls), we performed AML and MDS genome-wide association studies (GWAS) in European Americans and used these data sets to inform our hypothesis. To address the disease heterogeneity within and across our data we used a validated meta-analytic association test based on subsets (ASSET) (4) . ASSET tests the association of SNPs with all possible AML and MDS subtypes and identifies the strongest genetic association signal. To systematically test the association of genetically predicted gene expression with disease risk, we performed a transcriptome wide association study (TWAS) (10, 11) . This allows a preliminary investigation into the role of non-coding risk loci, which might be regulatory in nature, that impact expression of nearby genes. The TWAS statistical approach, PrediXcan (11) , was used to impute tissue-specific gene expression from a publicly available whole blood transcriptome panel into our AML and MDS cases and controls. The predicted gene expression levels were then tested for association with AML and MDS. The use of both a GWAS and TWAS in the DISCOVeRY-BMT study population allowed us to identify AML and MDS associations with IRF4, a transcription factor which regulates myeloid and lymphoid hematopoietic differentiation, and has been previously identified in GWAS of BCM. (5) 
MATERIALS AND METHODS

Study Design & Population
Our study was a nested case-control design derived from the parent study
DISCOVeRY-BMT (Determining the Influence of Susceptbility-COnveying Variants
Related to 1-Year Mortality after unrelated donor Blood and Marrow Transplant).(12)
The DISCOVeRY-BMT cohort was compiled from 151 centers around the world through the Center for International Blood and Marrow Transplant Research (CIBMTR). Briefly, the parent study was designed to find common and rare germline genetic variation associated with survival after an URD-BMT. DISCOVeRY-BMT consists of two cohorts of ALL, AML and MDS patients and their 10/10 human leukocyte antigen (HLA)matched unrelated healthy donors. Cohort 1 was collected between 2000 and 2008, Cohort 2 was collected from 2009-2011.
AML and MDS patients were selected from the DISCOVeRY-BMT patient cohorts and used as cases and all the unrelated donors from both cohorts as controls. AML subtypes included de novo AML with normal cytogenetics, de novo AML with abnormal cytogenetics and therapy-related AML (t-AML). De novo AML patients did not have precedent MDS or chemotherapy or radiation for prior cancers. MDS subtypes included de novo MDS, defined as patients without precedent chemotherapy or radiation for prior cancers, and therapy-related MDS (t-MDS). Patient cytogenetic subtypes were available, however due to limited sample sizes for each cytogenetic risk group, we consider here only broad categories. Controls were unrelated, healthy donors aged 18-61 years who passed a comprehensive medical exam and were disease-free at the time of donation. All patients and donors provided written informed consent for their clinical data to be used for research purposes and were not compensated for their participation.
Genotyping, imputation, and quality control
Genotyping and quality control in the DISCOVeRY-BMT cohort has previously been described in detail (12) (13) (14) (15) . Briefly, samples were assigned to plates to ensure an even distribution of patient characteristics and genotyping was performed at the University of Southern California Genomics Facility using the Illumina Omni-Express BeadChip® containing approximately 733,000 single nucleotide polymorphisms (SNPs).(16) SNPs were removed if the missing rate was > 2.0%, minor allele frequency (MAF) < 1%, or for violation of Hardy Weinberg equilibrium proportions (P< 1.0x10-4).
Problematic samples were removed based on the SNP missing rate, reportedgenotyped sex mismatch, abnormal heterozygosity, cryptic relatedness, and population outliers. Population stratification was assessed via principal components analysis using Eigenstrat software(17) and a genomic inflation factor (λ) was calculated for each cohort. Following SNP quality control, 637,655 and 632, 823 SNPs from the OmniExpress BeadChip in Cohorts 1 and 2, respectively were available for imputation. SNP imputation was performed using Haplotype Reference Consortium, hg19/build 37 (http://www.haplotype-reference-consortium.org/home) via the Michigan Imputation server (18, 19) . Variants with imputation quality scores <0.8 and minor allele frequency (MAF) <0.005 were removed yielding almost 9 million high quality SNPs available for analysis in each cohort.
METHODS
Statistical Analysis
Quality control and statistical analyses were implemented using QCTOOL-v2, R 3.5.2 (Eggshell Igloo), Plink-v1.9, and SNPTEST-v2.5.4-beta3. Logistic regression models adjusted for age, sex, and three principal components were used to perform single SNP tests of association with de novo MDS, t-MDS, AML by subtype (de novo AML with normal cytogenetics, de novo AML with abnormal cytogenetics and t-AML) in each cohort. European American healthy donors were used as controls. SNP meta-analyses of cohorts 1 and 2 were performed by fitting fixed effects models with inverse variance weighting using the R package Metafor. Random effects models were used to provide meta-analyses estimates if heterogeneity was detected between cohorts, defined as Cochran's Q value >50 or P <.05. To identify the strongest association signal with AML and MDS we conducted a summary statistic SNP-based association analysis (ASSET) implemented in R statistical software (4) . ASSET tests each SNP for association with outcome using an exhaustive search across non-overlapping AML and MDS case groups while accounting for the multiple tests required by the subset search, as well as any shared controls between groups (4).
Transcriptome-wide association study (TWAS)
To prioritize GWAS findings and identify expression quantitative trait loci (eQTL)-linked genes, we carried out a gene expression tests of association of de novo AML and MDS using PrediXcan (11) . This method leverages the well-described functional regulatory enrichment in genetic variants relatively close to the gene body (i.e. cis-regulatory variation) to inform models relating SNPs to gene expression levels in data with both gene expression and SNP genotypes available. Robust prediction models are then used to estimate the effect of cis-regulatory variation on gene expression levels. Using imputation, the cis-regulatory effects on gene expression from these models can be predicted in any study with genotype measurements, even if measured gene expression is not available. Thus, we imputed the cis-regulatory component of gene expression into our data for each individual using models trained on the whole blood transcriptome panel (n = 922) from the Depression Genes and Networks (DGN) (20) , yielding expression levels of 11,200 genes for each case and control. The resulting estimated gene expression levels were then used to perform gene-based tests of differential expression between AML and MDS cases and controls adjusted for age and sex. A fixed effects model with inverse variance weighting using the R package Metafor was used for meta-analysis of cohorts 1 and 2. A Bonferroni-corrected transcriptome wide significance threshold was set at P<4.5x10-6.
Functional Annotation of Genetic Variation associated with AML and MDS
To better understand the potential function of the variants identified by GWAS and ASSET analyses we annotated significant SNPs using publicly available data. eQTLGen, a consortium analyses of the relationship of SNPs to gene expression in 30,912 whole blood samples, was used to determine if significant and suggestive SNPs (p<5 x 10-6) were whole blood cis-eQTL, defined as allele specific association with gene expression (21) . Genotype-Tissue Expression project (GTEx) was used to test for significant eQTLs in >70 additional tissues (22) . AML and MDS SNP associations were also placed in context of previous GWAS using Phenoscanner, a variant-phenotype comprehensive database of large GWAS, which includes results from the NHGRI-EBI GWAS catalogue, the UK Biobank, NIH Genome-Wide Repository of Associations between SNPs and Phenotypes and publicly available summary statistics from more than 150 published genome association studies. Results were filtered at P < 5 x 10-8 and the R statistical software package phenoscanner (https://github.com/phenoscanner/phenoscanner) was used to download all data for our significant variants (23 (25) (26) (27) . Lastly, we sought to identify promoter interaction regions (PIR), defined as significant interactions between gene promotors and distal genomic regions. Variants in PIRs can be connected to potential gene targets and thus can impact gene function (27) . Briefly Hi-C libraries, enriched for promoter sequences, are generated with biotinylated RNA baits complementary to the ends of promoter-containing restriction fragments. Promoter fragments become bait for pieces of the genome that are targets with which they frequently interact, allowing regulatory elements and enhancers to be pulled down and sequenced. Statistical tests of bait-target pairs are done to define significant PIRs and their targets (25, 28, 29) . To identify the genomic features with which our significant SNPs might be interacting via chromatin looping we used publicly available Promoter Capture Hi-C (PCHi-C) data on a lymphoblastoid cell line (LCL), GM12878, and two ex vivo CD34+ hematopoietic progenitor cell lines (primary hematopoietic G-CSF mobilized stem cells and hematopoietic stem cells) (28) . We integrated our SNP data with the PCHi-C cell line data and visualized these interactions using circos plots (30) .
RESULTS
DISCOVeRY-BMT cases and controls
Results of quality control have been described elsewhere. (14) Following quality control, the DISCOVeRY-BMT cohorts include 1,769 AML and 540 MDS patients who received URD-BMT as treatment and 2,814 unrelated donors as controls ( Table 1 ). The majority of AML cases are de novo (N=1618) with normal cytogenetics (N=543), 6% of patients had therapy-related AML (t-AML). The most frequently reported previous cancers in patients with t-AML were breast (N=51), Non-Hodgkin Lymphoma (NHL), N=23, HL (N=14), Sarcoma (N=12), Gynecologic (N=8), Acute Lymphoblastic Leukemia (N=6) and Testicular (N=6). Prior therapies for these patients were approximately equally divided between single agent chemotherapy and combined modality chemotherapy plus radiation. Almost half of MDS patients had Refractory Anemia with Excess Blasts (RAEB) -1 and RAEB-2. Of patients with t-MDS (~18% of MDS patients), 65% had antecedent hematologic cancers or disorders. The most frequently reported antecedent cancers in MDS patients were NHL (N=27), breast (N=15), Acute Lymphoblastic Leukemia (N=8), HL (N=8), AML (N=8), Sarcoma (N=6) and CLL (N=5) ( Table 1) .
SNP Associations with AML and MDS
GWAS of AML by subtype (abnormal cytogenetics, normal cytogenetics and t-AML) and To identify loci that show association with AML and MDS we used ASSET. For SNPs to be considered, we used previously defined criteria, which required ASSET SNP associations at P ≤ 5.0 × 10−8 with significant individual one-sided subset tests (P < 0.01), the variant could not be driven a single disease nor could it be both positively and negatively associated in different cohorts of the same disease (5) In the ASSET GWAS analyses we identified a novel SNP associated with AML and MDS on Chromosome 6 (Figure 1) . The T allele at rs12203592, a variant in intron 4 of Interferon Regulatory Factor 4 (IRF4), was identified to confer increased risk of de novo abnormal cytogenetic AML, de novo normal cytogenetic AML, MDS and t-MDS (OR=1.38; 95% CI, 1.26-1.51, Pmeta=2.8 x 10-12). While T-AML showed no association with this variant, t-MDS did contribute to the association signal. The effect allele frequency was 19% in de novo AML, MDS and t-MDS cases versus 14% in controls. ASSET analyses also identified another variant in modest linkage disequilibrium (r2=.7) with rs12203592 in the regulatory region of IRF4; the A allele at rs62389423, showed a putative association with de novo AML and MDS (OR=1.36; 95% CI, 1.21-1.52, Pmeta=1.2x10-7) (Figure 2a ).
Functional Annotation of SNP associations with AML and MDS
Multiple GWAS of healthy individuals have shown associations between the T allele at rs12203592 and higher eosinophil counts, lighter skin color, lighter hair, less tanning ability, and increased freckling. (5, 26, 28, 36) . (Figure 3 and Supplemental Figure   2 ).
Transcriptome-wide association study -PrediXcan
Using PrediXcan(11) gene expression imputation models trained on the DGN data set, we identified one transcriptome wide significant gene associated with de novo AML and MDS. Increased expression of IRF4 was associated with an increased risk for the development of de novo AML and MDS (OR=3.90; 95% CI, 2.36-6.44, Pmeta=1.0x10-7), consistent with our SNP-level findings (Figure 4) .
Whole blood transcriptome models also identified two additional genes with suggestive associations with de novo AML and MDS. Increased expression of AKT Serine/Threonine Kinase 1, AKT1 at 14q32.33 was associated with risk for the development of de novo AML and MDS (OR=1.56; 95% CI, 1.25-1.95, Pmeta=1.0 x10-4) ( Figure 4) . Likewise, increased expression of Ras guanyl nucleotide-releasing protein 2, RASGRP2, was associated with an increased risk for development of de novo AML and MDS (OR=4.05; 95% CI, 1.84-8.91, Pmeta=5x10-4) (Figure 5) .
DISCUSSION
We performed the first large scale AML and MDS GWAS in a URD-BMT population providing evidence of novel pleotropic risk loci associated with increased susceptibility to AML and MDS. Using an alternative approach, ASSET, we provide the first genome wide significant evidence of association between a common variant and susceptibility to AML and MDS. We identified an association between the T allele at rs12203592 in IRF4 and an increased risk for the development of de novo AML, de novo MDS and t-MDS in patients who had undergone URD-BMT compared to healthy donor controls. Therapyrelated myeloid neoplasms have been shown to be genetically and etiologically similar to other high-risk myeloid neoplasms (37) , however in our transplant population t-AML did not associate with this variant, while t-MDS did show evidence of association with rs12203592. Although the therapy-related associations suffer from the tyranny of small sample sizes, the distribution of antecedent cancers differed significantly between t-MDS and t-AML, with almost 2/3 of t-MDS and 1/3 of t-AML patients diagnosed with a prior hematologic cancer, respectively.
The rs12203592 SNP has been shown to regulate IRF4 transcription by physical interaction with the IRF4 promoter through a chromatin loop (38) . This SNP resides in an important position within NFkB motifs in multiple blood and immune cell lines, supporting the hypothesis that this SNP may modulate NFkB repression of IRF4 expression. (39, 40) Furthermore, this SNP resides in a hematopoietic transcription factor that has been previously identified to harbor a hematological cancer susceptibility locus. While not in linkage disequilibrium (LD) with the CLL and Hodgkin Lymphoma susceptibility variant, PCHi-C data suggests chromatin interactions between the regions containing both SNPs. These data add to the mounting evidence that there could be pleiotropic genes across multiple hematologic cancers. Imputed gene expression logistic regression models showed a significant association between higher predicted levels of IRF4 expression and the risk for development of de novo AML or MDS (11) . Although IRF4 functions as a tumor suppressor gene in early Bcell development (41) , in multiple myeloma IRF4 is a well-established oncogene (35) , with oncogenic implications extending to adult leukemias (42) and lymphomas (43) , as well as pediatric leukemia. IRF4 overexpression is a hallmark of activated B-cell-like type of diffuse large B-cell lymphoma and associated with classical Hodgkin lymphoma (cHL), plasma cell myeloma and primary effusion lymphoma. (44) In a case-control study of childhood leukemia increased IRF4 expression was higher in immature B-common acute lymphoblastic leukemia and T-cell leukemia with the highest expression levels in pediatric AML patients compared to controls (45) . In addition to the CLL genetic susceptibility loci identified in IRF4, high expression levels of the gene have been shown to correlate with poor clinical prognosis (46) . TWAS studies can be a powerful tool to help prioritize potentially causal genes. It is, however, imperative to investigate the SNP and gene-expression associations in the context of the surrounding variants and genes to reduce the possibility of a false signal from co-regulation. Co-regulation can occur when there are multiple GWAS and TWAS hits due to linkage disequilibrium and thus it becomes difficult to determine which locus is driving the phenotypic association. In our study, the SNP rs12203592 is a significant eQTL for only IRF4, this implies that the SNP and imputed gene expression signal we identified is not being driven by co-regulation of neighboring SNPs and/or genes. When considering non-imputed gene expression sets, eQTLgen(21) corroborates this finding;
rs12230592 is significantly associated with only increased expression of IRF4. In addition, the relationship of rs12203592 to IRF4 expression in blood seems tissue specific, as GTEx data across over 70 tissues shows association with only lung tissue at P=9.1x10-9. The specificity of rs12203592 to IRF4 expression in blood and the lack of correlation between IRF4 expression and other genes in DISCOVeRY-BMT give confidence that the observed ASSET association is the potential susceptibility locus in the region. The functional significance of variants in this gene in hematopoiesis and its previous recognition as a locus associated with the risk for development of other hematological malignancies, further strengthen the evidence of an association of IRF4 with development of AML and MDS.
In addition to IRF4, we identified an association between the risk for development of de novo AML or MDS and higher expression of AKT1. AKT1 is an oncogene which plays a critical role in the PI3K/AKT pathway. AML patients frequently show increased AKT1 activity, providing leukemic cells with growth and survival promoting signals(47) and enhanced AKT activation has been implicated in the transformation from MDS to AML and overexpression of AKT has been shown to induce leukemia in mice. (48) We also identified AML and MDS gene expression associations with RASGRP2, which is expressed in various blood cell lineages and platelets, acts on the Ras-related protein Rap and functions in platelet adhesion. GWAS have identified significant variants in this gene associated with immature dendritic cells (% CD32+) and immature fraction of reticulocytes, a blood cell measurement shown to be elevated in patients with MDS versus controls.(31) RASGRP2 expression has not been studied in relation to AML or MDS, however recently RASGRP2/Rap1 signaling was shown to be functionally linked to the CD38-associated increased CLL cell migration. The migration of CLL cells into lymphoid tissues because of proliferation induced by B-cell receptor activation is thought to be an important component of CLL pathogenesis. (49) This finding has implications for the design of novel treatments for CD38+ hematological diseases. (49) These data imply the replication of these gene expression associations with the development of AML and MDS are warranted. This is the largest genome wide AML and MDS susceptibility study to date. Despite our relatively large sample size, the complexity of cytogenetic risk groups in these diseases limits our analysis. The DISCOVeRY-BMT study population is comprised of European American non-Hispanics and thus validation of these associations in a non-white cohort of patients is imperative. While previous genome wide scans have been done for t-AML(2) and AML in European American cases and controls and these authors did not report our association with IRF4, these cohorts were smaller and did not include MDS or AML patients who were receiving an allogeneic transplant as curative therapy for their disease. Lastly, the use of TWAS is a powerful way to start to prioritize causal genes for follow-up after GWAS, however there are limitations. TWAS tests for association with genetically predicted gene expression and not total gene expression, which includes environmental, technical and genetic components. (50) Our results provide evidence for the impact of common variants on the risk for AML or MDS susceptibility. Further characterization of the 6p25.3 locus might provide a more mechanistic basis for the pleiotropic role of IRF4 in AML and MDS susceptibility. The co-identification of variants in IRF4 associated with the risk for both myeloid and lymphoid malignancy supports the importance of broader studies that span the spectrum hematologic malignancies. All authors reviewed and approved the manuscript. 
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Figure 1. ASSET analysis and associations by AML and MDS subgroup
Forest plot of the odds ratios (OR) for the association between rs12203592 in IRF4 and MDS and AML subtypes. The variant resides in the Chromosome 6 outside the major histocompatibility complex region. Studies were weighted by inverse of the variance of the log (OR). The solid grey vertical line is positioned at the null value (OR=1); values to the right represent risk increasing odds ratios. Horizontal lines show the 95% CI and the box is the OR point estimate for each case-control subset with its area proportional to the weight of the patient group. The diamond is the overall effect estimated by ASSET, with the 95% CI given by its width.
Figure 2. IRF4 region with AML and MDS associated SNP p-values annotated with previous GWAS and Roadmap
Epigenome Chromatin States.
Figure 3. Significant chromatin interactions between the promoter region containing AML and MDS susceptibility variant, rs12203592 and all target regions.
The circular plots show significant chromatin looping interactions, defined as a CHICAGO score >=5, designated with red arcs, generated by promoter capture HI-C experiments in multiple cell lines. Moving from the outside of the circles inward we see base pair position on chromosome 6 in Kb, genes in grey (DUSP22, IRF4, EXOC2, HUS1B , etc) and the ENCODE roadmap epigenome ChromHMM states for (LEFT) E116: lymphoblastoid cell line and the following cell lines (RIGHT) E035:Primary hematopoietic stem cells; E036:Primary hematopoietic stem cells short term culture; E-50:Primary hematopoietic stem cells G-CSF mobilized Female; E-51:Primary hematopoietic stem cells G-CSF mobilized Male. In both left and right, there are significant interactions between the active TSS region containing rs12203592 and the region containing the previously identified CLL and HL susceptibility variant, rs9392017. 
Figure 5. Regional plots of PrediXcan-TWAS and SNP associations with AML and MDS
Each box represents PrediXcan-TWAS significant genes AKT1, IRF4 and RASGRP2 +/-0.5 megabases. The grey shaded bars represent the gene, where height is gene expression association and width is gene region in base pairs and the purple dots represent SNP associations with AML and MDS -log10 (P-values) are shown on the y-axis. Green and red lines denote the transcriptome-wide and genome wide significant P-values, respectively.
